Final Update: Jan 6, 2022 | Companies listed: 94
| Company | Drugs, Targets, Platforms | Therapeutic Areas, Indications | Lead Phase |
|---|---|---|---|
| Immix Biopharma, Inc. | Polykinase inhibitor (polyphenol curcuminoid complex), apoptosis inducer (PEG-PE doxorubicin complex) GLUT-1 scFv | Soft tissue sarcoma, solid tumors, CRC, IBD | I/II |
| Bionomics Limited | alpha-7 nAChR negative allosteric modulator, alpha-7 nAChR positive allosteric modulator, Nav1.7/1.8 inhibitors, Kv3.1/3.2 activators | PTSD, Social anxiety disorder, cognitive deficits in Alzheimer's | II |
| Genenta Science S.p.A. | Tie2-expressing monocytes, ex-vivo HSPC transduction with lentiviral vectors (Tie-2 promoter+transgene payloads) IFN-a | Glioblastoma multiforme, solid tumors + hematologic malignancies | I/IIa |
| NeuroSense Therapeutics Ltd. | Formulation of ciprofloxacin and celecoxib | ALS, Alzheimer's, Parkinson's | II |
| Cingulate, Inc. | Timed-release formulations of dexmethylphenidate, dextroamphetamine | ADHD, anxiety | III |
| Intensity Therapeutics, Inc. | Cell-penetration enhancer (8-((2-hydroxybenzoyl)amino)octanoate) combined with cisplatin and vinblastine | Advanced soft tissue sarcoma, breast cancer (early-stage, TNBC), CRC, bile duct, pancreatic, squamous cell, hepatic cancers | II+ |
| Nuvectis Pharma, Inc. | Synthetic lethality, oral HSF1 inhibitor, oral SRC/YES1 kinase inhibitor | Advanced solid tumors (ovarian clear cell carcinoma, endometrioid ovarian carcinoma, ARID1a mutated tumors) | I |
| Vaxxinity, Inc. | B-cell epitopes linked to T helper cell peptide carriers. Aggregated Aβ, aggregated a-synuclein, anti-tau, CGRP, PCSK9, SARS-CoV-2 virus | Alzheimer's, Parkinson's, DLB, MSA, Migraine, Hypercholesterolemia, Covid-19 | II |
| IO Biotech, Inc. | Immuno-oncology, IDO, PD-L1, Arginase 1 | 1L advanced melanoma, 1L solid tumors (+pembrolizumab), neo-adjuvant solid tumors, solid tumors | II+ |
| Evotec SE | iPSC-derived cell therapy, GABA-A, P2X3, CDK7, P2X7, mTORC1/2, 5-HT1A, CB2, A2A, VEGFR3, eIF2b, numerous partnered | Insomnia, chronic cough, overactive bladder, neuropathic pain, endometriosis, oncology, gynaecology, oncology, Pemphigus Vulgaris, OCD, pain | III |
| Aura Biosciences, Inc. | Virus-like drug conjugates | Primary choroidal melanoma, Choroidal metastases, SCC, melanoma, non-muscle invasive bladder cancer, HSPG-expressing tumors | II+ |
| Entrada Therapeutics | Exon 44 skipping oligonucleotide, exon 45 skipping oligonucleotide, CUG steric blocker, GYS1 knockdown, CD33 exon 2 skipper, IRF5 knockdown, B-catenin degrading antibody, ENTR-501 enzyme | DMD, Myotonic Dystrophy Type 1, Pompe, neurodegenerative diseases, inflammatory, solid tumors, MNGIE | Preclin |
| Xilio Therapeutics | Anti-CTLA4 (protease-dependent activity for TME), modified recombinant cytokines (IL-2, IL-12, IL-15) | Solid tumors | I |
| Ventyx Biosciences | Tyk2, S1P1R, NLRP3 oral inhibitors | Psoriasis, psoriatic arthritis, Crohn's disease, Ulcerative colitis | II |
| Context Therapeutics | Progesterone receptor antagonist, CLDN6xCD3 bsAb, Sigma1 | mBCa (1L, 2L/3L), Granulosa Cell Tumor, Recurrent Endometrial, Gyn cancers | II |
| MiNK Therapeutics, Inc. | iNKT cell therapy | Solid tumors, MM, GvHD, COVID-19 ARDS | I |
| AEON Biopharma | Injectable botulinum toxin | Cervical dystonia, migraine prevention | II |
| Cognition Therapeutics | TMEM97 (σ-2 antagonist) | Alzheimer's, Dementia, dry AMD, synucleinopathies | II |
| Pyrix Oncology | Anti EDB, Anti-DLK1, Anti-CD123 ADCs | Solid/hematological malignancies | Preclin |
| Theseus Pharmaceuticals | pan-variant TKIs (KIT, EGFR) | GIST, NSCLC (single-, double- triple-mutant EGFR) | IND |
| Exscientia | AI/data analytics, 5-HT1A | OCD | I |
| DICE Therapeutics | IL-17, integrin inhibitors (a4b7, avbx) | Psoriasis, IL-17 mediated chronic immunological disorders, IBD, fibrosis, oncology | IND |
| Tyra Biosciences | FGFR3 (V555) FGFR2, RET, FGFR4 | Oncology, bladder, bile duct, solid tumors, achondroplasia, NSCLC, thyroid, liver | Preclin |
| Pasithea Therapeutics | IV Ketamine | Psychiatric, neurological disorders (MDD, TRD, PTSD) | R&D |
| Pharmacyte Biotech | Encapsulated genetically engineered live cells implants | Pancreatic, abdominal cancers, type 1/2 diabetes | II |
| Dermata Therapeutics | Spongilla lacustris-derived compounds | Acne, Psoriasis, Rosacea, Hyperhidrosis, Aesthetics | II |
| RenovoRx | Targeted delivery of chemotherapy | Pancreatic, HCCA | III |
| Tango Therapeutics | PRMT5 MTA-cooperative inhibitor, USP1 inhibitor | MTAP-deleted cancers, BRCA-1 mutant cancers | Preclin |
| Eliem Therapeutics | PEA prodrug, GABAA PAM positive allosteric modulator, Kv7 | Diabetic nephropathic pain, lumbosacral pain, major depressive disorder, pain, epilepsy, | IIa |
| Adagio Therapeutics | Antibodies | COVID, Influenza | II/III |
| Omega Therapeutics | HNF4A, CXCL1-8, MYC, SFRP1 | Liver regeneration, COVID, IPF, HCC, NSCLC, SCLC, alopecia | Preclin |
| Immuneering Corp. | Dual MEK, KRAS4B, PI3K-alpha | KRAS cancers, oncology, Alzheimer's | I |
| Tenaya Therapeutics, Inc. | AAV, HDAC6i MYBPC3, PKP2, DWORF | gHCM, gARVC, HFrEF, HFpEF heart failure, gDCM cardiomyopathy | Preclin |
| Icosavax, Inc. | RSV, hMPV bivalent VLP vaccine candidates | RSV, COVID | I |
| Rallybio Corp. | Polyclonal HPA-1a, C5 inhibitor affibody-ABD fusion, pegylated affibody C5, ENPP1 | Prevention of FNAIT, PNH, gMG, HPP | I+ |
| Nuvalent, Inc. | Brain-penetrant ROS1-selective inhibitor | ROS1 NSCLC, ALK NSCLC, HER2 NSCLC | IND |
| Context Therapeutics | Extended release onapristone, Anti-CD3xClaudin 6 (CLDN6) | Breast cancer, ovarian, endometrial | II |
| Candel Therapeutics | Oncolytic viruses - adenovirus, HSV | PC, Glioma, NSCLC, pancreatic | III |
| Elicio Therapeutics, Inc. | mKRAS, TLR9, CD19, ALK, COV | PDAC, CRC, NSCLC, hematological, COVID | I |
| Caribou Biosciences | CAR T, iPSC derived CAR-NK | Allogeneic anti-CD19 CAR T, anti-BCMA CART, CAR-iNK | I |
| AbSci Corp. | AI | - | |
| HCW Biologics Inc. | Bifunctional fusion protein complex, TGFB, SASP | Pancreatic, solid tumors, pulmonary fibrosis, alopcia areata | IND |
| Erasca, Inc. | ERK, SHP2, EGFR, KRAS G12C, RAS-GTP, KRAS G12D, ULK, RAS/MAPK, EGFR D2/D3 | RAS/MAPK altered solid tumors, EGFRm altered NSCLC, FLT3m, GBM | II |
| TScan Therapeutics | CAR T TCRs HA-1 and HA-2 specific | AML, MDS, ALL, HNSCC, cervical, anal, NSCLC, melanoma | Preclin |
| Imago BioSciences, Inc. | LSD1 inhibitor | Thrombocytopenia, myelofibrosis, polycythemia vera, hemoglobinopathies, solid tumors | II |
| Unicycive Therapeutics | Prodrug of nicorandil , lanthanum-based phosphate binding agent | AKI | |
| Transcode Therapeutics, Inc. | RNA therapeutics, miR-10b | Oncology | IND |
| Acumen Pharmaceuticals, Inc. | Anti-amyloid-beta oligomer (AβO) antibody | AD/Alzheimer's | I |
| Aerovate Therapeutics, Inc. | Inhaled imatinib | PAH | |
| Elevation Oncology, Inc. | Anti-HER3 | NRG1 fusion tumors | II+ |
| Graphite Bio, Inc. | Gene editing HSC, B globin, IL2RG, CCR5 | SCD, XSCID cure, Gaucher | |
| GH Research plc | 5-MeO DMT psychedelic | Treatment resistant depression TRD | |
| Acurx Pharmaceuticals, LLC | Antibiotics | Bacteria | |
| Monte Rosa Therapeutics | GSPT1, CDK2, NEK7, VAV1, BCL11A targeted protein degradation | MYC cancers, ovarian, uterine, BC, inflammatory diseases | Pre-IND |
| Cyteir Therapeutics | Synthetic lethality, RAD51 inhibitor | Solid tumors, hematologic malignancies | I/II |
| Ambrx Biopharma | Anti-HER2 ADC, Anti-PSMA ADC, anti-CD70 ADC, PEG-IL-2, Anti-CD3 folate bis, TLR agonist ADC, | Gastric/GEJ cancer, solid tumors, mCRPC, NSCLC, ovarian, RCC, NHL, AML | III |
| ATAI Life Sciences B.V. | Psychedelics | Psychiatric | |
| Century Therapeutics, Inc. | Allogeneic iPSC-derived NK and T cell therapy, CD19, CD133 x EGFR, CD19 x CD79b | Oncology | Preclin |
| Verve Therapeutics | PCSK9, ANGPTL3 | Heterozygous familial hypercholesteremia, familial HCS | IND |
| Lyell Immunopharma, Inc. | Epigenetic reprogramming CAR t cells | ROR1+ NSCLC, NY-ESO-1 | |
| Molecular Partners AG | FAP x 4-1BB, FAPxCD40, CD3xCD33xCD70xCD123, T cell engagers | Oncology, COVID, nAMD, DME | I |
| Alzamend Neuro | Lithium, mutant peptide vaccine for AD | Dementia related to AD | |
| Janux Therapeutics, Inc. | PSMA x CD3, EGFR x CD3, TROP2 x CD3, PD-L1 x CD28 bispecifics | mCRPC, CRC, TNBC, UC, NSCLC, Solid tumors | IND |
| Centessa Pharmaceuticals plc | Vasopressin V2R, Protein C, Anti-EGFR, A1AT folding corrector, Anti-LIGHT, anti-BDCA2, CD47 lockbody, OX2R agonist, Dual STAT3/5 degrader, EGFR-ex20, EGFR-C797S | Autosomal dominant polycystic kidney disease, hemophilia A, B, cutaneous squamous cell carcinoma, alpha-1 antitrypsin deficiency, PAH, IPF, systemic sclerosis, SLE, solid tumors, narcolepsy, AML, NSCLC | III |
| Day One Biopharmaceuticals Holding Co | pan-RAF inhibitor, MEK1/2 inhibitor | relapsed pLGG, RAF-altered solid tumors, MAPK-altered solid tumors | II |
| Vera Therapeutics, Inc. | Anti-BLyS x APRIL (recombinant TACI) (licensed from Merck/atacicept) | IgA nephropathy | IIb |
| Anebulo Pharmaceuticals, Inc. | CB1 antagonist | Cannibinoid intoxication | |
| Talaris Therapeutics | Autologous cells reprogrammed | Solid organ transplantation, severe autoimmune disease | |
| Gyroscope Therapeutics | Gene therapy, complement | Dry AMD, GA | II |
| Valneva SE | Vaccines | Lyme, COVID, ZIKA, C Dificil | |
| Vaccitech plc | HBV, MERS | Vaccines, oncology | |
| Werewolf Therapeutics, Inc. | IL-2 conditionally activated, IL-12, IFNa | Tumors | IND |
| Rain Therapeutics Inc. | MDM2 inhibitor | Lipsarcoma, intimal sarcoma, HRD+ tumors | III |
| Recursion Pharmaceuticals | AI DATA ANALYTICS, MEK1/2, PKC and GSK3B, HDAC, superoxide scavenger, | Familial adenomatous polyposis (FAP), GM2 gangliosidosis, neurofibromatosis type 2, cerebral cavernous malformation, Batten, Charcot-Marie-Tooth, STK11-mutant NSCLC | I+ |
| Biomea Fusion | Menin inhibitor, precision oncology | Menin-dependent cancers | IND |
| Reneo Pharmaceuticals | PPAR agonist | Primary mitochondrial myopathies, long-chain fatty acid disorders, glyocgen storage disease type V | II |
| VectivBio Holding AG | Apraglutide (GLP-2 analog full agonist) | Short bowel syndrome, aGVHD | III |
| Achilles Therapeutics | Personalised CAR T | NSCLC, Melanoma, HNSCC, RCC | |
| Design Therapeutics | GeneTAC DNA binding | Friedreich ataxia FA, Myotonic dystrophy type I | Preclin |
| Edgewise Therapeutics | Fast skeletal muscle myosin inhibitor | DMD, LGMD, Cardiac | I |
| Ikena Oncology | TEAD, ERK5, AHR, Kynurenine, EP4, | Hippo-mutated cancers, KRAS mutant, solid tumors, biomarker enriched MSS CRC | I |
| IN8Bio | Autologous Gamma-delta T cells CAR | Solid tumors, GBM | |
| Lava Therapeutics | Gamma-delta T cell engagers | r/r CLL, MM, AML, mCRPC, solid tumors | I |
| Finch Therapeutics Group | Probiotics | Recurrent C. dificile, UC, Crohn's, Autism, Chronic HBV | II+ |
| Instil Bio | TIL Manufacturing | Melanoma, NSCLC, HNSCC, Cervical, CSCC, GYN | II |
| Gain Therapeutics | GLB1 gene GBA1 gene IDUA gene GALC gene | GM1 gangliosidosis, Gaucher, Parkinson's, MPS type I, Krabbe | Lead Op |
| Terns Pharmaceuticals | FXR agonist, VAP-1 inhibior, THR-B agonist, GLP-1R agonist | NASH | Iia |
| Angion | HGF mimetic, TKI, ROCK2 inhibitor, CYP11B2 inhibitor | Acute kidney injury (transplant), cardiac surgery-acute kidney injury, ARDS, acute CNS-related injury, Fibrosis | III |
| Nanobiotix | Radioenhancer nanomedicine | Oncology | |
| Bolt Biotherapeutics | TLR7/8 agonist-trastuzumab conjugate, Anti-HER2, Anti-CEA, Anti-PD-L1, Anti-TAM | HER2+ BC, HER2+ GC, HER2 low BC, NSCLC, CRC, Pancreatic, checkpoint-inhibitor refractory tumors, KRAS/TP53 mutant tumors | I/II |
| Sensei Biotherapeutics | Immunophage ASPH, HPV-specific E6/E7, Phage, Anti-VISTA | ASPH+ 1L HNSCC +pembrolizumab, neoadjuvant HNSCC + durvulumab, Merkel cell carcinoma | II |
| Immunocore Holdings | Recombinant TCRs - gp100 antigen, MAGE-A4 antigen, PRAME antigen, NY-ESO antigen, HBV Env, HIV gag | Uveal melanoma, NSCLC, gastric, HNSCC, ovarian, synovial sarcoma, breast, endometrial, ovarian, SCLC, HBV, HIV | BLA |
| Longboard Pharmaceuticals | 5-HT2c agonist, CB2 agonist, S1p receptor | Epileptic encephalopathies (Dravet, Lennox-Gastaut), ALS, Neuroinflammation | I |
| Prometheus Biosciences | Anti-TL1A, Anti-TNF super family, GPCR modulator | UC, CD, IBD | I |